
DWTX
Dogwood Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.9937
Open
4.800
VWAP
4.86
Vol
11.81K
Mkt Cap
9.35M
Low
4.760
Amount
57.33K
EV/EBITDA(TTM)
--
Total Shares
1.91M
EV
92.47M
EV/OCF(TTM)
--
P/S(TTM)
--
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Show More
2 Analyst Rating

309.00% Upside
Wall Street analysts forecast DWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DWTX is 20.00 USD with a low forecast of 10.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy

309.00% Upside
Current: 4.890

Low
10.00
Averages
20.00
High
30.00

309.00% Upside
Current: 4.890

Low
10.00
Averages
20.00
High
30.00
HC Wainwright & Co.
Sean Lee
Hold
to
Strong Buy
Upgrades
$10
2025-04-23
Reason
HC Wainwright & Co.
Sean Lee
Price Target
$10
2025-04-23
Upgrades
Hold
to
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Dogwood Therapeutics Inc (DWTX.O) is -0.84, compared to its 5-year average forward P/E of -2.18. For a more detailed relative valuation and DCF analysis to assess Dogwood Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.18
Current PE
-0.84
Overvalued PE
-0.75
Undervalued PE
-3.61
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
YoY :
+237.11%
-4.43M
Operating Profit
FY2025Q1
YoY :
+746.02%
-10.92M
Net Income after Tax
FY2025Q1
YoY :
+402.98%
-8.45
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DWTX News & Events
Events Timeline
2025-05-08 (ET)
2025-05-08
09:02:57
Dogwood sees cash runway through 1Q26

2025-05-08
09:02:16
Dogwood reports Q1 EPS ($8.45) vs. ($1.68) last year

2025-04-11 (ET)
2025-04-11
09:21:50
Dogwood receives Nasdaq confirmation of compliance

Sign Up For More Events
Sign Up For More Events
News
9.0
08-07NewsfilterPinnedDogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
1.0
06-03NewsfilterDogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
4.0
04-23BenzingaHC Wainwright & Co. Upgrades Dogwood Therapeutics to Buy, Announces $10 Price Target
Sign Up For More News
People Also Watch

CYCC
Cyclacel Pharmaceuticals Inc
8.780
USD
-2.12%

BBLG
Bone Biologics Corp
2.330
USD
-8.27%

BDRX
Biodexa Pharmaceuticals PLC
7.130
USD
+4.85%

WINT
Windtree Therapeutics Inc
0.547
USD
-6.81%

CNEY
CN Energy Group Inc
2.100
USD
-3.67%

DGLY
Digital Ally Inc
1.780
USD
-2.47%

ISPC
iSpecimen Inc
1.280
USD
-28.89%

RNAZ
Transcode Therapeutics Inc
10.390
USD
-2.44%
FAQ

What is Dogwood Therapeutics Inc (DWTX) stock price today?
The current price of DWTX is 4.89 USD — it has decreased -0.04 % in the last trading day.

What is Dogwood Therapeutics Inc (DWTX)'s business?

What is the price predicton of DWTX Stock?

What is Dogwood Therapeutics Inc (DWTX)'s revenue for the last quarter?

What is Dogwood Therapeutics Inc (DWTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Dogwood Therapeutics Inc (DWTX)'s fundamentals?

How many employees does Dogwood Therapeutics Inc (DWTX). have?
